Cell-based therapies are being developed for various neurodegenerative diseases that
affect the central nervous system (CNS). Concomitantly, the roles of individual cell types in …

Autoimmune diseases (ADs) represent a heterogenous group of complex diseases with
increasing incidence in Western countries and are a major cause of morbidity …

Autologous haematopoietic stem cell transplantation (aHSCT) is gaining traction as a
valuable treatment option for patients affected by severe multiple sclerosis (MS), particularly …

Introduction In 1995, the use of autologous hematopoietic stem-cell transplantation
(AHSCT), which was previously used to treat hematological tumors, was introduced for …

Development of disease-modifying therapies including monoclonal antibody (mAb)-based
therapeutics for the treatment of multiple sclerosis (MS) has been extremely successful over …

Multiple sclerosis (MS) is a chronic debilitating immune‐mediated disease of the central
nervous system, which causes demyelination and neuroaxonal damage. Low‐grade …

Hematopoietic stem cells have been investigated and applied for the treatment of certain
neurological disorders for a long time. Currently, their therapeutic potential is harnessed in …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that
affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing …

Systemic sclerosis (SSc) is a systemic disease characterized by autoimmune responses,
vasculopathy and tissue fibrosis. The pathogenic mechanisms involve a wide range of cells …

In this study, we aimed to assess the quality of life, fatigue, anxiety, and depression after
Autologous haematopoietic stem cell transplantation (AHSCT) and to investigate its impact …